Open Access Open Access  Restricted Access Subscription or Fee Access

NEWEST RESEARCH ON FUNGAL MEDICATIONS

S Shameem, Dr.S Kameshwaran, K. Shanmugapriya, A. Saranya, K.P. Sathish, S.M. Shabariraj

Abstract


Mycosis is a disorder brought on by mould or yeast, commonly known as a fungal infection. Although fungi (plural of fungus) can spread diseases to the mouth, throat, lungs, urinary tract, and many other regions of the body, skin and nails are the most common sites for fungal infections. You will experience various symptoms depending on the kind of fungus infection you have and where it is on your body. The symptoms are most often detected on the vaginal, throat, and mouth mucous membranes. Symptoms can occasionally be brought on by infections of the sinuses, brain, eyes, digestive tract, and lungs. Numerous fungal infections can be cured with the use of antifungal drugs, which get rid of fungus on and in your body. Depending on the fungus's location

Keywords


Fungal infections, Mucous membranes, Sinuses, Mycosis, vagina

Full Text:

PDF

References


https://my.clevelandclinic.org/health/diseases/24401-fungal-infections-mycosis .Retrievedon :25 Jun 2023.

G Garber.An overview of fungal infections. Drugs.2001;61 Suppl 1:1- 12.DOI:10.2165/00003495-200161001-00001.

Sheridan M Hoy.Oteseconazole: First Approval.Drugs.2022 Jun;82(9):1017- 1023.DOI:10.1007/s40265-022-01734-y.

Drug Bank Oteseconazole https://go.drugbank.com/drugs/DB13055.Retrievedon:26Jun2023.

Jingxiang Zhang , Liping Li , Quanzhen Lv , Lan Yan , Yan Wang , Yuanying Jiang. The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors. Front Microbiol.2019 Apr 24;10:691. DOI: 10.3389/fmicb.2019.00691

FDA Approved Drug Products: Vivjoa (oteseconazole) oral capsules https://www.fda.gov/media/141068/download [Link]. Jun 30 2023.

https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial- resistance-information-fda

https://www.rxlist.com/oteseconazole/generic-drug.htm Retrievedon July 3 2023.

Mark G. Martens, Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections,July18,2022.DOI:https://doi.org/10.1016/j.ajog.2022.07.023

Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004). Combination antifungal therapy. Antimicrobial agents and chemotherapy, 48(3), 693-715.

https://www.fda.gov/drugs/development-resources/rezafungin-injection

https://www.mskcc.org/cancer-care/patient-education/medications/rezafungin. Retrievedon :Jul10 2023.

Allana J Sucher 1, Annie Thai 1, Charlene Tran 1, Netra Mantena 2, Allwyn Noronha 2,Elias B Chahine 2.Ibrexafungerp: A new triterpenoid antifungal.2022 Dec 5;79(24):2208-2221.DOI:10.1093/ajhp/zxac256.

SabelleJallow1,*andNeleshP.Govender1.Ibrexafungerp:AFirst-in- ClassOralTriterpenoidGlucanSynthaseInhibitor.2021 Mar;7(3):163.Doi:10.3390/jof7030163.

Stephen A Wring , Ryan Randolph , SeongHee Park , George Abruzzo , Qing Chen , Amy Flattery , Graig Garrett , Michael Peel , Russell Outcalt , Kendall Powell , Michelle Trucksis , David Angulo , Katyna Borroto-Esoda. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02068-16. DOI: 10.1128/AAC.02068-16.

WringS,MurphyG,AtieeG,CorrC,HymanM,WillettM,AnguloD:ClinicalPharmacokineti csandDrug-DrugInteractionPotentialforCoadministeredSCY- 078,anOralFungicidalGlucanSynthaseInhibitor,andTacrolimus.ClinPharmacolDrugDev .2019Jan;8(1):60-69.doi:10.1002/cpdd.588.

Mahmoud Ghannoum , Maiken Cavling Arendrup , Vishnu P Chaturvedi , Shawn R Lockhart , Thomas S McCormick , Sudha Chaturvedi , Elizabeth L Berkow , Deven Juneja , Bansidhar Tarai , Nkechi Azie , David Angulo , Thomas J Walsh .Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections.Antibiotics. 2020 Aug 25;9(9):539. DOI: 10.3390/antibiotics9090539.

FDA Approved Drug Products https://www.fda.gov/drugs/development- resources/antifungal-susceptibility-test-interpretive-criteria

Hernández A, Ruiz-Moyano S, Galván AI, Merchán AV, Pérez Nevado F, Aranda E, Serradilla MJ, Córdoba MG, Martín A. Anti-fungal activity of phenolic sweet orange peel extract for controlling fungi responsible for post-harvest fruit decay. Fungal Biol. 2021 Feb;125(2):143-152. doi: 10.1016/j.funbio.2020.05.005. Epub 2020 Jun 14. PMID: 33518204.

https://www.webmd.com/drugs/2/drug-181635/ibrexafungerp- oral/details#:~:text=Nausea%2C%20stomach%2Fabdominal%20pain%2C,your%20d octor%20or%20pharmacist%20promptly.Retrived onJul 132023.

Karen Joy Shaw , Ashraf S Ibrahim.A Review of the First-in-Class Broad Spectrum Agent for theTreatment of Invasive Fungal Infections.J Fungi (Basel). 2020 Oct 22;6(4):239.Doi:10.3390/jof6040239.

“GWT1”.SaccharomycesGenomeDatabase.StanfordUniversity https://cherrylab.stanford.edu/projects/saccharomyces-genome-database Retrieved2022-06-28.

Shaw KJ, Ibrahim AS (October 2020). “Fosmanogepix: A Review of the First- in-Class BroadSpectrum Agent for the Treatment of Invasive Fungal Infections”. Journal of Fungi. 6 (4): 239.Doi:10.3390/jof6040239.

Shaw KJ, Ibrahim AS (October 2020). “Fosmanogepix: A Review of the First- in-Class BroadSpectrum Agent for the Treatment of Invasive Fungal Infections”. Journal of Fungi. 6 (4): 239.Doi:10.3390/jof6040239.

Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M (September 2021). “Antimicrobialactivity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporaryinvasive fungal isolates from an international surveillance programme (2018-2019)”. Journal ofGlobalAntimicrobialResistance.26: 117–127.Doi:10.1016/j.jgar.2021.04.012.

Arendrup, M.; Chowdhary, A.; Astvad, K.M.T.; Jørgensen, K.M. APX001A In vitro Activity againstContemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method.Antimicrob.AgentsChemother.2018,62,AAC.01225–18,doi:10.1128/aac.01 225-18.

Zhao, Y.; Lee, M.H.; Paderu, P.; Lee, A.; Jimenez-Ortigosa, C.; Park, S.; Mansbach, R.S.; Shaw, K.J.;Perlin, D.S. Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 againstEchinocandinand Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis.Antimicrob.AgentsChemother.2018,62,AAC.00425–18,doi:10.1128/aac. 00425-18

Martin Hoenigl,corresponding author, Rosanne Sprute,Matthias Egger, Amir Arastehfar, Oliver A.Cornely, Robert Krause, Cornelia Lass-Flörl, Juergen Prattes,Andrej Spec, George R. Thompson, III,Nathan Wiederhold,and Jeffrey D. Jenks.The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp,Olorofim, Opelconazole, and Rezafungin.Springer link .2021; 81(15): 1703–1729. Doi:10.1007/s40265-021-01611-0.

“Karen Joy Shaw and Ashraf S. Ibrahim,Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections, 2020 Oct 22,6(4) doi: 10.3390/jof6040239.

FosmanogepixAmplyxPharmaceuticals”.AdisInsight.RetrievedJune27,2022.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Pharmacology